AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31)
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) of 6 Y for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-18.
Discontinued › Notes › Compensation Related Costs
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm · last filed 2013-03-18
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2012 was 6.00 Y, a 0.00% change from fiscal 2011.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2011 was 6.00 Y, a 0.00% change from fiscal 2010.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, expected term (deprecated 2012-01-31) for fiscal 2010 was 6.00 Y.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Deprecated 2012-01-31) 12 month |
|---|---|
| 2012-12-31 | 6.00 Y 10-K · filed 2013-03-18 |
| 2011-12-31 | 6.00 Y 10-K · filed 2013-03-18 |
| 2010-12-31 | 6.00 Y 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |